NCT06191744 2026-04-13
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
Clinical Trials
20 trialsNCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT01712490 2026-02-27
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
Phase 3 Completed
NCT06831370 2026-02-23
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Takeda
Phase 4 Recruiting
NCT04980222 2026-02-17
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06356129 2026-02-12
GOLSEEK-1
Celgene
Phase 3 Active not recruiting
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT05673785 2025-07-14
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Takeda
Phase 2 Active not recruiting
NCT01974440 2025-05-25
SELENE
Janssen Research & Development, LLC
Phase 3 Completed
NCT01855750 2025-02-04
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT05406401 2024-10-15
waveLINE-007
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT01777152 2021-11-30
ECHELON-2
Seagen Inc.
Phase 3 Completed
NCT01889069 2020-08-13
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Hoffmann-La Roche
Phase 3 Completed
NCT00451178 2020-07-21
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
Eli Lilly and Company
Phase 2 Completed
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT01309789 2017-06-28
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Seagen Inc.
Phase 1 Completed
NCT01831505 2017-02-27
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Presage Biosciences
Phase 1 Completed
NCT02486952 2016-02-22
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
Hoffmann-La Roche
Completed
NCT01060904 2014-12-18
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
Seagen Inc.
Phase 1 Completed